ASN
PTGX icon

Advisory Services Network’s Protagonist Therapeutics PTGX Stock Holding History

Advisory Services Network’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9K Buy
+18
New +$1.59K ﹤0.01% 4153
2025
Q4 		– Sell
-9
Closed -$598 – 3657
2025
Q3 		$598 Buy
+9
New +$512 ﹤0.01% 4023

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Advisory Services Network's PTGX Position: Q1 2026 in Review

Advisory Services Network opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 18 shares worth $1.9K. The stake represents ﹤0.01% of the portfolio and ranks #4153 among its holdings. This is a return to the name: Advisory Services Network previously reported a position in PTGX as recently as Q3 2025.

Advisory Services Network first reported a position in PTGX in Q3 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Advisory Services Network held 18 shares of Protagonist Therapeutics worth $1.9K as of Q1 2026.
  • Protagonist Therapeutics was a new Advisory Services Network position in Q1 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #4153 holding.
  • Advisory Services Network first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.